Skip to main content

A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab

Recruiting · Phase 2 · NCT06524635

Conditions: Hidradenitis Suppurativa, Atopic Dermatitis

At a glance

Research payments reported, 2025
$549,478
U.S. investigators named
2
Sites paid
2
Planned or actual enrollment
60

About the trial

Sponsor
AbbVie
Tested
Lutikizumab (drug)
Dates
Started 2024-08-14; completion 2027-02
Results posted
Not yet

Hidradenitis suppurativa (HS) and atopic dermatitis (AD) are chronic inflammatory skin diseases that lead to the development of skin lesions and symptoms such as pain and discomfort. The purpose of this study is to assess molecular changes in adult participants with moderate to severe HS or with moderate to severe AD. Lutikizumab (ABT-981) is an investigational drug being developed for the treatment of HS and AD. This study will consist of 2 sub-studies: Sub-Study 1 moderate to severe hidradenitis suppurativa and Sub-Study 2 moderate to severe atopic dermatitis. Approximate 60 participants will be enrolled in the study at approximately 2 sites in the US. In Sub-Study 1 HS participants wil…

From ClinicalTrials.gov, last updated 2025-01-24. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $549,478 in research payments for this study in 2025 (41 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.